Kylie G Nairon

Kylie G Nairon

Auto-generated profile, based on publicly available information

Kylie G Nairon

Vanderbilt Institute for Clinical & Translational Research, Vanderbilt University Medical Center , Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
JFJeffrey A Freiberg
Jeffrey A Freiberg
EQEdward T Qian
Edward T Qian
KNKylie G Nairon
Kylie G Nairon
BEBenjamin J Ereshefsky
Benjamin J Ereshefsky
CHCassandra Hennessy
Cassandra Hennessy
AZAutumn D Zuckerman
Autumn D Zuckerman
Background: Fear of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of community-acquired pneumonia (CAP) frequently leads to empiric vancomycin coverage. Data evaluating the use of MRSA polymerase chain reaction (PCR) nasal swab testing to guide vancomycin de-escalation is limited for patients in the intensive care unit (ICU). Methods: Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc) is a pragmatic, prospective, single-center, non-blinded randomized trial in which adult ICU patients with suspicion of CAP were randomized 1:1 to receive usual care either with (intervention) or without (control) the addition of MRSA nares PCR testing following ICU admission. The primary outcome was vancomycin-free hours alive, defined as the expected number of hours alive and free of vancomycin use within the first 7 days of trial enrollment as estimated using a longitudinal proportional odds state transition model adjusted for baseline covariates. Results: A total of 277 adult ICU patients were randomized. Methicillin-resistant Staphylococcus aureus PCR nasal swab testing had a negative predictive value (NPV) of 98.9% in the intervention arm. The primary endpoint, vancomycin-free hours alive, was 105.7 in the control arm and 109.7 in the intervention arm (adjusted difference, 4 hours; 95% CI, −9.5–18.2; P = .458). Conclusions: Despite MRSA PCR nasal swab testing demonstrating a high NPV in this critically ill population, MRSA PCR nasal swab testing did not decrease the duration of vancomycin use or 30-day mortality among ICU patients with suspected CAP. Additional clinician education and antimicrobial stewardship interventions might be needed to reduce vancomycin use in this patient population. Clinical Trials Registration: ClinicalTrials.gov NCT06272994 (STOP-Vanc).

10 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SASydney R. Anderson
Sydney R. Anderson
TKTilak Khanal
Tilak Khanal
KNKylie G. Nairon
Kylie G. Nairon
Aleksander SkardalAleksander Skardal
Aleksander Skardal
WCWilliam E Carson
William E Carson
MRMatthew D. Ringel
Matthew D. Ringel
Background: Study of the metastatic cascade in differentiated non-medullary thyroid cancer (NMTC) is hampered by the relative lack of preclinical models that metastasize from primary tumors to other organs. We previously identified regulator of calcineurin 1 isoform 4 (RCAN1.4) as a suppressor of NMTC cell growth, invasion, and metastasis using in vitro systems and tail vein injections in immunocompromised mice. We then reported a microfluidic device mimicking the mouse tail vein injection where cancer cells were allowed to flow directly to lung organoid constructs. We now report the development of a full primary tumor to lung metastasis-on-a-chip (MOC) model for TC. Methods: Resin molds for primary and secondary sites connected by a channel were 3D-printed and filled with polydimethylsiloxane to create a molded silicone elastomer. The primary site was seeded with an organoid composed of a hyaluronic acid and collagen-based hydrogel into which FTC236 and HTh74 NMTC cells with and without knockdown of RCAN1.4 were engrafted. The secondary site consisted of a hydrogel organoid into which bronchial epithelial cells and lung fibroblasts were seeded. Culture media was circulated and movement of NMTC cells to the secondary site was assessed. Results: Both cell lines that expressed RCAN 1.4 metastasized to the secondary lung site. RCAN1.4-reduced FTC236 cells had increased metastatic behavior vs controls while HTh74 was less affected by RCAN1.4 loss, similar to prior studies. To determine if the MOC could be used for incorporation of immune components and therapeutic modeling, NK-92 cells were added and were shown to be reduce metastases for both cell lines in the presence or absence of RCAN1.4. Analysis of MOC circulating fluid revealed elevated levels of granzyme B, consistent with NK-92 cell activation. Cytokine profiling identified elevated probable NMTC and NK-92-derived factors. Conclusions: These results indicate that NMTC metastatic behavior can be modeled using a novel MOC system for mechanistic and preclinical therapeutic studies.